Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve...
Month: July 2024
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to CalidiSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE)...
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
Teladoc Health Introduces Pediatric, Adolescent and Family Mental Healthcare Through Partnership with Brightline
Seamless access to a comprehensive range of mental healthcare options provides swift, early intervention and treatment for kids and teens,...
Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain
On track to initiate Phase 1b/2a clinical trial of AB126 in acute ischemic stroke in 2H 2024BOSTON and ATHENS, Ga.,...
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications...
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin...
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Best-in-class just got better; Smith+Nephew announces 510(k) clearance of new CATALYSTEM™ Primary Hip System
Engineered for precision, confidence and efficiency in surgery - and compatible with the CORI◊ Surgical System Smith+Nephew (LSE:SN, NYSE:SNN), the...
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
Repligen to Report Second Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ETWALTHAM, Mass., July 16, 2024 (GLOBE...
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing...
Streamline Health® Expands RevID™ Agreement With 400-Bed Children’s Health System
DC-based Children’s health system expands utilization of RevID to improve charge capture and financial performance, extends to 5-year termATLANTA, July...
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and...
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
- Results will be presented at the London International Cough Symposium on July 18, 2024 - Dose dependent cough suppression...
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden...